Valuation: Tsubota Laboratory Incorporated

Market Cap 662.91Cr 4.21Cr 3.7Cr 3.49Cr 3.18Cr 5.96Cr 403.75Cr 6Cr 42Cr 16Cr 206.27Cr 16Cr 15Cr P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 572.81Cr 3.64Cr 3.19Cr 3.02Cr 2.75Cr 5.15Cr 348.87Cr 5.18Cr 36Cr 14Cr 178.23Cr 14Cr 13Cr EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
12/08 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
17/06 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
15/05 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
15/05 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
13/02 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
13/02 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/25/12 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/25/17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/24/20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/22/19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/22/20 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 day-0.77%
1 week-1.15%
Current month-13.76%
1 month-5.86%
3 months+18.98%
6 months-27.81%
Current year-24.41%
1 week 255
Extreme 255
264
1 month 251
Extreme 251
305
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Others

Founder

63,000 0.2465%
15/11/24 Others

Founder

4,20,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-1.15%-26.78%-49.90% 4.2Cr
-0.14%+4.44%+8.50%+33.52% 4.8TCr
-1.69%+1.48%+53.02%+33.59% 4.53TCr
+0.24%+2.85%+9.78%+89.54% 4.09TCr
+2.56%+7.34%+382.17%+594.81% 4.28TCr
-0.62%-1.61%+5.30%+46.02% 2.96TCr
-0.28%+1.07%+26.83%+152.91% 1.73TCr
-0.46%+0.62%+24.98%+41.01% 1.53TCr
-2.21%-4.70% - - 1.52TCr
+3.37%+9.21%+9.93% - 1.48TCr
Average -0.05%+0.88%+54.86%+117.69% 2.69TCr
Weighted average by Cap. +0.04%+1.56%+81.56%+154.22%

Financials

2025 2026
Net sales 135.7Cr 86.23L 75.67L 71.46L 65.13L 1.22Cr 83Cr 1.23Cr 8.55Cr 3.31Cr 42Cr 3.24Cr 3.17Cr 20Cr 12.71L 11.15L 10.53L 10L 17.97L 12Cr 18.1L 1.26Cr 48.82L 6.22Cr 47.72L 46.69L
Net income 20Cr 13.03L 11.43L 10.8L 10L 18.42L 12Cr 18.55L 1.29Cr 50.04L 6.38Cr 48.91L 47.85L -76Cr -48.36L -42.43L -40.08L -36.52L -68.37L -46Cr -68.86L -4.8Cr -1.86Cr -24Cr -1.82Cr -1.78Cr
Net Debt -144.8Cr -92.01L -80.74L -76.26L -69.49L -1.3Cr -88Cr -1.31Cr -9.13Cr -3.53Cr -45Cr -3.45Cr -3.38Cr -90Cr -57.25L -50.24L -47.45L -43.24L -80.95L -55Cr -81.52L -5.68Cr -2.2Cr -28Cr -2.15Cr -2.1Cr
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
25/26/25 JP¥257.00 -0.77% 15,600
24/26/24 JP¥259.00 -1.89% 25,600
18/26/18 JP¥264.00 +1.54% 15,000
17/26/17 JP¥260.00 +1.56% 24,100
16/26/16 JP¥256.00 -4.48% 59,300
  1. Stock Market
  2. Stocks
  3. 4890 Stock